Although as well as a nonsignificant interaction between tDCS and AD risk factors, there was a statistical trend toward an interaction between tDCS and the APOE ε4-allele, possibly attributable to increased aMPFC DC after tDCS application in MCI patients with Aβ deposits, yielding a large effect size (p = 0.056, partial η2 = 0.138, Figure 1A). The gene discussed is APOE; the disease is Alzheimer disease.